Stoke Ther­a­peu­tics un­veils more da­ta on stud­ies of Dravet drug, hint­ing at im­prove­ments to cog­ni­tion and be­hav­ior

Stoke Ther­a­peu­tics pre­sent­ed more da­ta on its in­ves­ti­ga­tion­al Dravet syn­drome treat­ment on Tues­day morn­ing, say­ing it helped re­duce seizures and im­prove cer­tain cog­ni­tive and be­hav­ioral func­tions, but the 45 mg da­ta were well be­low an­a­lyst ex­pec­ta­tions and in­vestors sent the stock $STOK down near­ly 40% be­fore the open­ing bell.

It’s still a lim­it­ed look at the stud­ies, though, and more da­ta are need­ed from two open-la­bel Phase I/IIa tri­als and an ex­ten­sion study be­fore fi­nal­iz­ing Phase III plans next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER